Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.47 |
| ▸ | NPC1 | O15118 | 6/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489036 | 0.87 | TRPV1 (0.48) | RAB9ANPC1DYRK1AHTTMEN1 | |
| SCHEMBL27038236 | 0.86 | RAB9A (0.50) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL28125063 | 0.83 | HDAC6 (0.53) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24330810 | 0.81 | HDAC6 (0.68) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9320873 | 0.81 | RAB9A (0.49) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5946306 | 0.80 | APP (0.49) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL28125064 | 0.80 | APP (0.46) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6273815 | 0.79 | RAB9A (0.63) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL20509831 | 0.79 | UBE2T (0.58) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL31003075 | 0.79 | RAB9A (0.63) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021139814-A1 | QUINOLINE IMIDAZOLE COMPOUND AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2021-07-15 | — | — | WO | disclosed |
| US-20190315731-A1 | 6-(BUTA-1,3-DIYN-1-YL)BENZO[D]THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS, LTD. (CH) | 2019-10-17 | — | — | US | disclosed |
| EP-3221300-B1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-03-20 | — | — | EP | disclosed |
| US-20170355687-A1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-12-14 | — | — | US | disclosed |
| US-20120108637-A1 | Fused Bicyclic-Substituted Amines as Histamine-3 Receptor Ligands | ABBOTT LABORATORIES (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108637-A1 | Fused Bicyclic-Substituted Amines as Histamine-3 Receptor Ligands | ABBOTT LABORATORIES (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108637-A1 | Fused Bicyclic-Substituted Amines as Histamine-3 Receptor Ligands | ABBOTT LABORATORIES (US) | 2012-05-03 | — | — | US | disclosed |
| US-8106088-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106088-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106088-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2012-01-31 | — | — | US | disclosed |
| US-7358263-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358263-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358263-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| US-7094790-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060142325-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2006-06-29 | — | — | US | disclosed |
| EP-1620434-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | Abbott Laboratories (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20040248899-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2004101559-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040224953-A1 | e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight. | ABBOTT LABORATORIES | 2004-11-11 | — | — | US | disclosed |
| US-20040224952-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315731-A1 | 6-(BUTA-1,3-DIYN-1-YL)BENZO[D]THIAZOLE DERIVATIVES | TMBIM6, BTN3A1, BET1 | RAB9A 1760/4885NPC1 790/4885CYP1A2 920/4885 |
| US-20040248899-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | RAB9A 1268/4885NPC1 850/4885CYP1A2 1294/4885 |
| US-20040224953-A1 | e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight. | HRH4, HRH3, HRH2 | RAB9A 2349/4885NPC1 1618/4885CYP1A2 1602/4885 |
| US-20060142325-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH2 | RAB9A 1087/4885NPC1 1140/4885CYP1A2 1772/4885 |
| US-20120108637-A1 | Fused Bicyclic-Substituted Amines as Histamine-3 Receptor Ligands | HRH3, HRH4, HRH2 | RAB9A 1087/4885NPC1 1140/4885CYP1A2 1772/4885 |
| US-20040224952-A1 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | RAB9A 1268/4885NPC1 850/4885CYP1A2 1294/4885 |
| US-20170355687-A1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | CYP8B1, TUBB, DRD3 | RAB9A 1127/4885NPC1 2923/4885CYP1A2 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.